Israel-based Lipogen announced the intention to expand its production facilities and build a new phospholipids research and development center. According to the company, the operation is a consequence of the rapid, 50% increase in sales of brain and stress health solutions obtained in Q1-Q3 2015.

Panned investments amount to US$2.6 million for building two additional production lines for phosphatidylserine (PS) and phosphatidic acid (PA). The company also doubled production capabilities for PS and PA. The new plants include automated controlled processing to reduce production costs through improved production traceability, and implement new safety methods, allowing Lipogen to produce its all-natural, non-GMO, solvent-free ingredients in accordance with the highest industry standards.